Trump's divisive FDA vaccine regulator self-destructs, will exit agency (again)

March 11, 2026
Trump's divisive FDA vaccine regulator self-destructs, will exit agency (again)

Here's something that caught my attention — Vinay Prasad, a controversial figure at the FDA, is once again leaving the agency. Beth Mole reports that FDA Commissioner Marty Makary announced Prasad’s departure in April, claiming he achieved a lot during his year there. But here’s where it gets interesting — Prasad’s tenure was riddled with mistakes. According to Beth, he shockingly overruled scientists to reject an mRNA vaccine, only to reverse that decision quickly. Then there was the bizarre move demanding extra trials for a Huntington’s gene therapy, which many saw as moving the goalposts. And get this — he publicly attacked the gene therapy maker, UniQure, creating a toxic work environment, as staff alleged. Now, as Beth notes, these self-destructive choices seem to have finally caught up with him. So what does this all mean? It’s a reminder that even powerful regulators aren’t immune to making reckless decisions — something to keep in mind as the FDA’s reputation hangs in the balance.

For the second time, Vinay Prasad is set to leave the Food and Drug Administration.

In a post on social media Friday, FDA Commissioner Marty Makary announced that Prasad will exit in April, adding that he got "a tremendous amount accomplished" during his year at the agency.

Prasad's tenure was generally marked by controversy, but he is departing amid a cluster of self-destructive decisions. Those include a shocking rejection of an mRNA vaccine (which was over the objections of agency scientists and quickly reversed); a demand for an additional clinical trial on a gene therapy for Huntington's disease, which was widely seen as moving the goalpost for the therapy; his startling choice to publicly attack the maker of that gene therapy, UniQure; and alleged abuse of FDA staff, who say he created a toxic work environment.

Read full article

Comments

Audio Transcript

For the second time, Vinay Prasad is set to leave the Food and Drug Administration.

In a post on social media Friday, FDA Commissioner Marty Makary announced that Prasad will exit in April, adding that he got "a tremendous amount accomplished" during his year at the agency.

Prasad's tenure was generally marked by controversy, but he is departing amid a cluster of self-destructive decisions. Those include a shocking rejection of an mRNA vaccine (which was over the objections of agency scientists and quickly reversed); a demand for an additional clinical trial on a gene therapy for Huntington's disease, which was widely seen as moving the goalpost for the therapy; his startling choice to publicly attack the maker of that gene therapy, UniQure; and alleged abuse of FDA staff, who say he created a toxic work environment.

Read full article

Comments

0:00/0:00